ClinicalTrials.gg

Renal Insufficiency, Chronic clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 3,096 studies for Renal Insufficiency, Chronic across more than 10 countries. 701 are recruiting or about to start. 1,910 of them are mainly about Renal Insufficiency, Chronic (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17. Counting its narrower condition Kidney Failure, Chronic too: 4,880 studies, 919 open.

ClinicalTrials.gov finds 5,031 studies for Renal Insufficiency, Chronic. How that becomes 3,095 here

This page counts the studies the registry files under Renal Insufficiency, Chronic, and those it files under no condition that list Renal Insufficiency, Chronicthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 15, 2026. How condition pages count

  1. 5,031Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −1,700Filed under a narrower condition, counted on its own pageKidney Failure, Chronic 1,681
  3. −236Match it another way6 name it in the title and 230 by a synonym or other text the search reads.
  4. 3,095The count on this page

Status

Completed
1,634
Recruiting
435
Status unknown
346
Not yet recruiting
221
Terminated
180
Active, not recruiting
140

Phase

Phase 2
364
Phase 3
356
Phase 4
313
Phase 1
212
Early Phase 1
22

Where

United States
988
China
245
France
238
Germany
232
United Kingdom
229
Canada
215

Who develops what

Add Renal Insufficiency, Chronic to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 62 programs from 35 companies, 36 with this as their studies’ main aim; 18 with a live phase 3 study; 12 primary completions in the next 12 months. Compare AstraZeneca, Novo Nordisk and Eli Lilly here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
continuous erythropoietin receptor activatorRecent, limited
Evidence
  • NCT07119372 · Biocad · Phase 3 · live · comparator · “Mircera (methoxypolyethylene glycol-epoetin beta)” · registered Aug 2025
  • NCT04707768 · Akebia Therapeutics · Phase 3 · comparator · “Mircera®” · registered Jan 2021
  • NCT02791763 · GlaxoSmithKline · Phase 3 · comparator · “Epoetin beta pegol” · registered Jun 2016
  • NCT02044653 · Genexine, Inc. · Phase 2 · comparator · “MIRCERA” · registered Jan 2014
Hoffmann-La Roche99% of its industry studiesUS: HOFFMAN-LA ROCHE (FDA 2007)EU: Hoffmann-La Roche (EMA 2007)11 study
CinacalcetRecent, limitedPhase 4 trial recorded
Evidence
  • NCT07122401 · Shaanxi Micot Pharmaceutical Technology Co., Ltd. · Phase 3 · live · comparator · “Cinacalcet” · registered Aug 2025
  • NCT02133404 · Astellas Pharma Inc · Phase 2 · comparator · “Cinacalcet” · registered Apr 2014
Amgen91% of its industry studies11 study
IrbesartanRecent, limited
Evidence
  • NCT07555054 · Hansoh Pharmaceutical Group Company Limited · Phase 2 · live · comparator · “Irbesartan” · registered Apr 2026
  • NCT05056727 · AstraZeneca · Phase 3 · background · “Irbesartan” · registered Sep 2021
Sanofi56% of its industry studiesUS: off-patent, 17 generics marketedEU: off-patent, 2 generics authorized11 study

12 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
vicadrostat☆ Track1 live phase-3 study: NCT06531824Boehringer Ingelheim
empagliflozinApproved: EU 2014☆ Track1 live phase-3 study: NCT07107945Boehringer Ingelheim
dapagliflozinApproved: US · EU☆ Track3 live phase-3 studies: NCT06742723, NCT07624305, NCT06268873AstraZeneca
baxdrostatApproved: US 2026☆ Track2 live phase-3 studies: NCT06742723, NCT06268873AstraZeneca
HRS-1780☆ Track1 live phase-3 study: NCT07419828Jiangsu HengRui Medicine Co., Ltd.

The 5 in phase 3 with the nearest primary completion, of 62 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (12)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 26 Nov 2026 est.MT1013 · Shaanxi Micot Pharmaceutical Technology Co., Ltd. · Phase 3 registry mapping only+ MT1013 vs CinacalcetNCT07122401 Study of MT1013 for the Treatment of Patients With Secondary Hyperparathyroidism — primary endpoint: Percentage of participants with > 50% reduction from baseline in mean intact parathyroid (iPTH) · 424 enrolled
  • Dec 2026 est.IGT-303 · Ingenia Therapeutics INC · Phase 2 main aimNCT07231679 A Study to Investigate IGT-303 in Healthy Volunteers and Participants With Chronic Kidney Disease — primary endpoint: Adverse events (AEs), serious adverse events (SAEs), and treatment-emergent adverse events (TEAEs) · 94 enrolled
  • 10 Dec 2026 est.dapagliflozin, baxdrostat · AstraZeneca · Phase 2 main aimNCT07222917 A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure. — primary endpoint: To determine whether baxdrostat/dapagliflozin is superior to baxdrostat/matching placebo at reducing albuminuria. · 222 enrolled

9 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Renal Insufficiency, Chronic studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here SGLT2 inhibitors 21 open · Mineralocorticoid receptor antagonists (MRAs) 17 open · GLP-1 receptor agonists 13 open · Diuretics 5 open · Angiotensin receptor blockers (ARBs) 2 open

Coming up

249studies finish main data collection within a year13 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 435 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger. 44 (10%) take children under 18. 5 (1%) are for women only and 2 (<1%) for men only; 80 (18%) take healthy volunteers.

Recruiting studies that take each age, of 435
AgeWomenMen
1031 (7%)32 (7%)
18349 (80%)348 (80%)
30363 (83%)362 (83%)
40373 (86%)372 (86%)
50387 (89%)383 (88%)
65393 (90%)389 (89%)
75357 (82%)354 (81%)
85294 (68%)292 (67%)

Across all 3,096 studies, recruiting or not: 24% stop at 75 or younger and 12% at 65; 10% take children; 1% are for women only and 1% for men only; 14% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Renal Insufficiency, Chronic studies take

Of 145 phase 3 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 32 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 111 mo5–27 · 109 studies7 mo5–16 · 77 studies—
Phase 1/225 mo12–55 · 22 studies——
Phase 225 mo15–43 · 139 studies19 mo12–31 · 80 studies41 mo23–62 · 59 studies
Phase 2/321 mo9–56 · 11 studies——
Phase 332 mo19–54 · 145 studies29 mo18–49 · 104 studies50 mo28–69 · 41 studies
Phase 443 mo22–67 · 116 studies—46 mo24–67 · 100 studies
Interventional, no phase23 mo10–45 · 618 studies23 mo10–43 · 40 studies23 mo10–45 · 578 studies
Observational45 mo22–191 · 327 studies29 mo17–51 · 51 studies59 mo23–192 · 276 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Started recruiting12

Show 7 more

Newly registered29

Show 24 more

Studies

Recruiting first, then most recently updated. Showing 50 of 3,096. Browse all 3,096 → or search them.